Innoviva, Inc. Files Amendment No. 2 to 2023 Annual Report

TL;DR

<b>Innoviva, Inc. has filed an amendment to its 2023 annual report, confirming its status as a large accelerated filer.</b>

AI Summary

Innoviva, Inc. (INVA) filed a Amended Annual Report (10-K/A) with the SEC on March 22, 2024. Innoviva, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in Burlingame, CA. Innoviva, Inc. is listed on The Nasdaq Stock Market LLC under the trading symbol INVA. The filing indicates Innoviva, Inc. is a large accelerated filer. The company has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Innoviva, Inc., this filing contains several important signals. This amendment suggests potential updates or corrections to the original annual filing, which could contain material information for investors. As a large accelerated filer, Innoviva is subject to more stringent SEC reporting requirements, indicating a certain level of financial maturity and public scrutiny.

Risk Assessment

Risk Level: low — Innoviva, Inc. shows low risk based on this filing. The filing is an amendment to a previous report, indicating potential revisions rather than new material events, thus posing a low immediate risk.

Analyst Insight

Review the specific changes made in Amendment No. 2 to the 10-K filing for any material updates to Innoviva's financial or operational status.

Key Numbers

• 2023-12-31 — Fiscal Year End (Innoviva, Inc. fiscal year end)
• 2024-03-22 — Filing Date (Date of Amendment No. 2 filing)
• 000-30319 — Commission File Number (SEC file number for Innoviva, Inc.)
• 94-3265960 — IRS Employer Identification No. (Innoviva, Inc. IRS number)

Key Players & Entities

• Innoviva, Inc. (company) — Registrant name
• 10-K/A (filing) — Form type
• December 31, 2023 (date) — Fiscal year end
• Delaware (jurisdiction) — State of incorporation
• Burlingame, CA (location) — Principal executive offices
• INVA (ticker) — Trading symbol
• The Nasdaq Stock Market LLC (company) — Exchange
• 2024-03-22 (date) — Filing date

FAQ

Industry Context

Innoviva, Inc. operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 13 or 15(d), which governs periodic reporting requirements for public companies.

What Investors Should Do

1. Review the full Amendment No. 2 filing for specific changes from the original 10-K.
2. Verify Innoviva's financial health and operational status based on the amended report.
3. Monitor future filings for any further updates or disclosures from Innoviva, Inc.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the annual report.
• 2024-03-22: Filing Date of 10-K/A Amendment No. 2 — Indicates the date the amended filing was submitted to the SEC.

Year-Over-Year Comparison

This is an amended filing (10-K/A), indicating revisions or additions to the previously submitted annual report for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.01 — ange On Which Registered Common Stock $0.01 Par Value INVA The Nasdaq Stock Mar

Filing Documents

• inva-20231231.htm (10-K/A) — 265KB
• inva-ex23_3.htm (EX-23.3) — 3KB
• inva-ex31_1.htm (EX-31.1) — 13KB
• inva-ex31_2.htm (EX-31.2) — 13KB
• inva-ex32.htm (EX-32) — 14KB
• inva-ex99_1.htm (EX-99.1) — 707KB
• 0000950170-24-035419.txt (&nbsp;) — 4912KB
• inva-20231231.xsd (EX-101.SCH) — 2663KB
• inva-20231231_htm.xml (XML) — 11KB

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a) The following documents are filed as part of this Amendment No. 2 on Form 10K/A: 1. Financial Statements: The following financial statements, supplementary data and reports of independent public accountants appear in Part II, Item 8 of the Original Filing and the Amendment No. 1 are incorporated herein by reference: Consolidated Balance Sheets as of December 31, 2023 and 2022 Consolidated Statements of Income for each of the three years in the period ended December 31, 2023 Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2023 Consolidated Statements of Stockholders' Equity for each of the three years in the period ended December 31, 2023 Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2023 Notes to the Consolidated Financial Statements Reports of Independent Registered Public Accounting Firm (PCAOB ID 34 ), Deloitte & Touche LLP , San Jose, CA Report of Independent Registered Public Accounting Firm (PCAOB ID 248) 2. Financial Statement Schedules: All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information. (b) Exhibits required by Item 601 of Regulation SK: The information required by this Item is set forth on the exhibit index that follows the signature page of this report. 4 Exhibits Incorporated by Reference Filed Herewith Exhibit Number Description Form Exhibit Filing Date/Period End Date 2.1 Agreement and Plan of Merger, dated as of May 23, 2022, by and among Innoviva, Inc., Innoviva Merger Sub, Inc. and Entasis Therapeutics 8-K 2.1 5/24/2022 2.2 Agreement and Plan of Merger, dated as of July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNOVIVA, INC. Date: March 22, 2024 By: /s/ PAVEL RAIFELD Pavel Raifeld Chief Executive Officer 8

View Full Filing

View this 10-K/A filing on SEC EDGAR